Archive · 18 Nov 2025
Pfizer's New Migraine Treatment Offers Hope in India
Pfizer has launched a new medicine called Rimegepant ODT in India for adults who get migraines.
This small tablet dissolves in your mouth without needing water.
It works quickly to stop migraine pain and keeps it away for up to two days.
This new treatment targets a specific thing in the body called CGRP, which is important in causing migraines.
It's different from other migraine medicines because it can also help prevent future migraines.
Migraines are a big problem in India, affecting many people and causing lost workdays.
Pfizer introduces Rimegepant ODT for acute migraine treatment in India.
Provides rapid and sustained pain relief lasting up to 48 hours post-treatment.
Convenient administration as an orally disintegrating tablet (ODT), no water required.
Targets adults who have previously had an insufficient response to triptan medications.
Migraine affects approximately 26.3% of people in Delhi NCR and 213 million people annually in India.
- Who
- Pfizer Ltd
- What
- Launches Rimegepant ODT for acute migraine treatment
- When
- November 17, 2025
- Where
- India
- Why
- To provide adults with acute migraine, who have had insufficient response to triptans, with rapid and sustained pain relief.
For Rimegepant ODT
Considerations
Treatment Efficacy
For Rimegepant ODT
Provides rapid and sustained pain relief lasting up to 48 hours post-treatment.
Considerations
Expected to help people manage pain more effectively and reclaim productive days sooner than current options.
Administration
For Rimegepant ODT
Convenient administration without water, in a 75 mg ODT form.
Considerations
Designed for adults who have had insufficient response to triptans.
Mechanism of Action
For Rimegepant ODT
Targets calcitonin gene-related peptide (CGRP), a key element of migraine pathophysiology.
Considerations
Offers prompt and effective relief by addressing a critical aspect of migraine.
- Drug Name
- Rimegepant ODT
- Dosage
- 75 mg
- Administration
- Orally disintegrating tablet (ODT), administered without water.
- Pain Relief Duration
- Up to 48 hours post-treatment
- Target Population
- Adults with acute migraine and a previous insufficient response to triptans.
- Mechanism of Action
- Targets calcitonin gene-related peptide (CGRP).
- Migraine Prevalence in Delhi NCR
- 26.3%
- Annual Migraine Cases in India
- 213 million
Sources
Pfizer launches new medication for migraine treatment
Pfizer launches new migraine drug in India; Rimegepant ODT promises 48-hour pain relief
Pfizer brings in Rimegepant, its novel Orally Disintegrating Tablet, to treat acute migraine
